Yahoo
HKSE - Delayed Quote HKD

Livzon Pharmaceutical Group Inc. (1513.HK)

24.580 +0.380 (+1.57%)
At close: November 6 at 4:08:50 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
10,223,743.024
12,020,349.220
11,812,338.855
12,430,038.326
12,629,579.048
Cost of Revenue
3,944,966.855
4,099,300.682
4,081,106.957
4,465,473.361
4,461,283.076
Gross Profit
6,278,776.169
7,921,048.537
7,731,231.898
7,964,564.965
8,168,295.972
Operating Expense
4,109,037.394
5,146,123.803
4,901,107.721
5,533,852.905
5,933,892.236
Operating Income
2,169,738.775
2,774,924.734
2,830,124.177
2,430,712.059
2,234,403.736
Net Non Operating Interest Income Expense
89,664.063
235,839.612
154,945.598
261,270.256
212,078.919
Pretax Income
2,198,452.800
2,862,050.545
2,806,146.268
2,382,666.546
2,330,550.610
Tax Provision
365,430.845
451,011.210
501,661.315
485,065.534
374,973.228
Net Income Common Stockholders
1,557,254.351
2,023,249.328
2,061,095.804
1,953,650.833
1,909,407.688
Basic EPS
1.76
2.27
2.24
2.10
2.04
Diluted EPS
1.76
2.27
2.24
2.10
2.04
Basic Average Shares
886,348.790
891,299.263
920,132.055
930,309.921
935,984.161
Diluted Average Shares
886,348.790
891,299.263
920,132.055
930,309.921
935,984.161
Total Operating Income as Reported
2,277,815.376
2,946,120.920
2,844,400.261
2,415,108.490
2,350,555.618
Total Expenses
8,054,004.249
9,245,424.485
8,982,214.678
9,999,326.267
10,395,175.312
Net Income from Continuing & Discontinued Operation
1,557,254.351
2,023,249.328
2,061,095.804
1,953,650.833
1,909,407.688
Normalized Income
1,652,780.593
2,100,574.919
2,191,671.750
2,232,037.258
2,074,001.728
Interest Income
181,254.063
297,577.267
247,956.637
368,159.120
315,137.488
Interest Expense
44,626.910
57,205.596
88,606.561
102,085.923
97,545.934
Net Interest Income
89,664.063
235,839.612
154,945.598
261,270.256
212,078.919
EBIT
2,243,079.710
2,919,256.140
2,894,752.828
2,484,752.469
2,428,096.544
EBITDA
2,243,079.710
3,493,282.287
3,469,888.936
3,325,076.101
3,080,420.588
Reconciled Cost of Revenue
3,944,966.855
4,099,300.682
4,081,106.957
4,465,473.361
4,461,283.076
Reconciled Depreciation
586,074.896
574,026.147
575,136.107
840,323.632
652,324.044
Net Income from Continuing Operation Net Minority Interest
1,557,254.351
2,023,249.328
2,061,095.804
1,953,650.833
1,909,407.688
Total Unusual Items Excluding Goodwill
-114,570.331
-91,790.187
-159,000.909
-349,547.674
-196,154.213
Total Unusual Items
-114,570.331
-91,790.187
-159,000.909
-349,547.674
-196,154.213
Normalized EBITDA
2,357,650.041
3,585,072.474
3,628,889.845
3,674,623.775
3,276,574.801
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-19,044.090
-14,464.595
-28,424.963
-71,161.250
-31,560.172
12/31/2022 - 1/16/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: